Very small size proteoliposomes derived from Neisseria meningitidis: An effective adjuvant for generation of CTL responses to peptide and protein antigens

Vaccine

Volumn 24, Issue 14, 2006, Pages 2692-2699

  Mesa, Circe ^a   De León, Joel ^a   Fernández, Luis E ^a  

^a CENTER OF MOLECULAR IMMUNOLOGY   (Cuba)

Author keywords

Cross priming; CTL; Neisseria meningitidis

Indexed keywords

ARGINYLALANYLHISTIDYLTYROSYLASPARAGINYLISOLEUCYLVALYLTHREONYLPHENYLALANINE; GAMMA INTERFERON; IMMUNOLOGICAL ADJUVANT; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; OVALBUMIN; PEPTIDE DERIVATIVE; SERYLISOLEUCYLISOLEUCYLASPARAGINYLPHENYLALANYLGLUTAMYLLYSYLLEUCINE; TUMOR CELL VACCINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIGEN PRESENTATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CROSS PRESENTATION; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DRUG EFFECT; DRUG RESPONSE; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; MOLECULAR SIZE; MOUSE; NEISSERIA MENINGITIDIS; NONHUMAN; PRIORITY JOURNAL; PROTEOLIPOSOME; T LYMPHOCYTE ACTIVATION; TUMOR REJECTION;

ADJUVANTS, IMMUNOLOGIC; ADJUVANTS, PHARMACEUTIC; ANIMALS; ANTIBODY FORMATION; ANTIGENS, BACTERIAL; CYTOTOXICITY, IMMUNOLOGIC; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NEISSERIA MENINGITIDIS; PEPTIDES; PROTEOLIPIDS; T-LYMPHOCYTES, CYTOTOXIC; VACCINES, SUBUNIT;

EID: 33344475049     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2005.08.111     Document Type: Article

References (39)

1. M.L. Albert, B. Sauter, and N. Bhardwaj Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs Nature 392 6671 1998 86 89
2. C.A. Janeway Jr., U. Dianzani, P. Portoles, S. Rath, E.P. Reich, and J. Rojo Cross-linking and conformational change in T-cell receptors: role in activation and in repertoire selection Cold Spring Harb Symp Quant Biol 54 Pt 2 1989 657 666
3. I. Miconnet, S. Koenig, D. Speiser, A. Krieg, P. Guillaume, and J.C. Cerottini CpG are efficient adjuvants for specific CTL induction against tumor antigen-derived peptide J Immunol 168 3 2002 1212 1218
4. S. Thoelen, P. Van Damme, C. Mathei, G. Leroux-Roels, I. Desombere, and A. Safary Safety and immunogenicity of a hepatitis B vaccine formulated with a novel adjuvant system Vaccine 16 7 1998 708 714
5. C. Mesa, and L.E. Fernandez Challenges facing adjuvants for cancer immunotherapy Immunol Cell Biol 82 6 2004 644 650
6. S. Ladisch, R. Li, and E. Olson Ceramide structure predicts tumor ganglioside immunosuppressive activity Proc Natl Acad Sci USA 91 5 1994 1974 1978
7. S. Ladisch, S. Kitada, and E.F. Hays Gangliosides shed by tumor cells enhance tumor formation in mice J Clin Invest 79 6 1987 1879 1882
8. F. Estevez, A. Carr, L. Solorzano, O. Valiente, C. Mesa, and O. Barroso Enhancement of the immune response to poorly immunogenic gangliosides after incorporation into very small size proteoliposomes (VSSP) Vaccine 18 1-2 1999 190 197
9. C. Mesa, J. De Leon, K. Rigley, and L.E. Fernandez Very small size proteoliposomes derived from Neisseria meningitidis: an effective adjuvant for Th1 induction and dendritic cell activation Vaccine 22 23-24 2004 3045 3052
10. R.F. Irie, D.W. Ollila, S. O'Day, and D.L. Morton Phase I pilot clinical trial of human IgM monoclonal antibody to ganglioside GM3 in patients with metastatic melanoma Cancer Immunol Immunother 53 2 2004 110 117
11. M.H. Ravindranath, M.C. Kelley, R.C. Jones, A.A. Amiri, P.M. Bauer, and D.L. Morton Ratio of IgG:IgM antibodies to sialyl Lewis(x) and GM3 correlates with tumor growth after immunization with melanoma-cell vaccine with different adjuvants in mice Int J Cancer 75 1 1998 117 124
12. D.P. Griswold, and T.H. Corbett A colon tumor model for anticancer agent evaluation Cancer 36 Suppl. 6 1975 2441 2444
13. D.F. Alonso, E.F. Farias, A. Urtreger, V. Ladeda, M.C. Vidal, and E. Bal De Kier Joffe Characterization of F3II, a sarcomatoid mammary carcinoma cell line originated from a clonal subpopulation of a mouse adenocarcinoma J Surg Oncol 62 4 1996 288 297
14. S. Sanderson, and N. Shastri LacZ inducible, antigen/MHC-specific T cell hybrids Int Immunol 6 3 1994 369 376
15. R.E. Toes, R. Offringa, M.C. Feltkamp, M.J. Visseren, S.P. Schoenberger, and C.J. Melief Tumor rejection antigens and tumor specific cytotoxic T lymphocytes Behring Inst Mitt 94 1994 72 86
16. K. Inaba, M. Inaba, N. Romani, H. Aya, M. Deguchi, and S. Ikehara Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor J Exp Med 176 6 1992 1693 1702
17. S.R. Scheffer, H. Nave, F. Korangy, K. Schlote, R. Pabst, and E.M. Jaffee Apoptotic, but not necrotic, tumor cell vaccines induce a potent immune response in vivo Int J Cancer 103 2 2003 205 211
18. C. Peschel, C. Huber, and W.E. Aulitzky Clinical applications of cytokines Presse Med 23 23 1994 1083 1091
19. A. Carr, Z. Mazorra, D.F. Alonso, C. Mesa, O. Valiente, and D.E. Gomez A purified GM3 ganglioside conjugated vaccine induces specific, adjuvant-dependent and non-transient antitumour activity against B16 mouse melanoma in vitro and in vivo Melanoma Res 11 3 2001 219 227
20. A. Carr, E. Rodriguez, M.C. Arango, R. Camacho, M. Osorio, and M. Gabri Immunotherapy of advanced breast cancer with a heterophilic ganglioside (NeuGcGM3) cancer vaccine J Clin Oncol 21 6 2003 1015 1021
21. A. Ribas, L.H. Butterfield, J.A. Glaspy, and J.S. Economou Current developments in cancer vaccines and cellular immunotherapy J Clin Oncol 21 12 2003 2415 2432
22. National Cancer Institute: National Cancer Institute's Physician Data Query, 2002. http://www.cancer.gov/search/clinical_trials/.
23. S.J. Jackson, and K.W. Singletary Sulforaphane: a naturally occurring mammary carcinoma mitotic inhibitor, which disrupts tubulin polymerization Carcinogenesis 25 2 2004 219 227
24. A.L. Hewitt, and K.W. Singletary Soy extract inhibits mammary adenocarcinoma growth in a syngeneic mouse model Cancer Lett 192 2 2003 133 143
25. A.M. Vazquez, M.R. Gabri, A.M. Hernandez, D.F. Alonso, I. Beausoleil, and D.E. Gomez Antitumor properties of an anti-idiotypic monoclonal antibody in relation to N-glycolyl-containing gangliosides Oncol Rep 7 4 2000 751 756
26. F.R. Carbone, C. Kurts, S.R. Bennett, J.F. Miller, and W.R. Heath Cross-presentation: a general mechanism for CTL immunity and tolerance Immunol Today 19 8 1998 368 373
27. J.A. Brinkman, S.C. Fausch, J.S. Weber, and W.M. Kast Peptide-based vaccines for cancer immunotherapy Expert Opin Biol Ther 4 2 2004 181 198
28. D. Lienard, D. Rimoldi, M. Marchand, P.Y. Dietrich, N. van Baren, and C. Geldhof Ex vivo detectable activation of Melan-A-specific T cells correlating with inflammatory skin reactions in melanoma patients vaccinated with peptides in IFA Cancer Immun 4 2004 4
29. P. Jeannin, T. Renno, L. Goetsch, I. Miconnet, J.P. Aubry, and Y. Delneste OmpA targets dendritic cells, induces their maturation and delivers antigen into the MHC class I presentation pathway Nat Immunol 1 6 2000 502 509
30. C.A. Colaco Towards a unified theory of immunity: dendritic cells, stress proteins and antigen capture Cell Mol Biol (Noisy-le-grand) 44 6 1998 883 890
31. N. Hanna, and K. Hariharan Development and application of PROVAX adjuvant formulation for subunit cancer vaccines Adv Drug Deliv Rev 32 3 1998 187 197
32. N.A. Sheikh, G.S. Attard, N. van Rooijen, P. Rajananthanan, K. Hariharan, and Y.W. Yang Differential requirements for CTL generation by novel immunostimulants: APC tropism, use of the TAP-independent processing pathway, and dependency on CD80/CD86 costimulation Vaccine 21 25-26 2003 3775 3788
33. J.W. Yewdell, C.C. Norbury, and J.R. Bennink Mechanisms of exogenous antigen presentation by MHC class I molecules in vitro and in vivo: implications for generating CD8+ T cell responses to infectious agents, tumors, transplants, and vaccines Adv Immunol 73 1999 1 77
34. D. Arnold, S. Faath, H. Rammensee, and H. Schild Cross-priming of minor histocompatibility antigen-specific cytotoxic T cells upon immunization with the heat shock protein gp96 J Exp Med 182 3 1995 885 889
35. T. Maurer, A. Heit, H. Hochrein, F. Ampenberger, M. O'Keeffe, and S. Bauer CpG-DNA aided cross-presentation of soluble antigens by dendritic cells Eur J Immunol 32 8 2002 2356 2364
36. G. Behrens, M. Li, C.M. Smith, G.T. Belz, J. Mintern, and F.R. Carbone Helper T cells, dendritic cells and CTL Immunity Immunol Cell Biol 82 1 2004 84 90
37. E.M. Janssen, E.E. Lemmens, T. Wolfe, U. Christen, M.G. von Herrath, and S.P. Schoenberger CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes Nature 421 6925 2003 852 856
38. J.F. Bukowski, M.G. Roncarolo, H. Spits, M.S. Krangel, C.T. Morita, and M.B. Brenner T cell receptor-dependent activation of human lymphocytes through cell surface ganglioside GT1b: implications for innate immunity Eur J Immunol 30 11 2000 3199 3206
39. S. Hakomori Tumor-associated carbohydrate antigens defining tumor malignancy: basis for development of anti-cancer vaccines Adv Exp Med Biol 491 2001 369 402